Boxer Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Boxer Capital’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,000,000	Closed	-$5.72M	–	68
2024 Q3	$5.72M	Sell	2,000,000 -2,475,000	-55%	-$7.66M	0.28%	52
2024 Q2	$13.1M	Hold	4,475,000	–	–	0.69%	37
2024 Q1	$14.3M	Buy	+4,475,000	New	+$14.9M	0.71%	38
2021 Q3	–	Sell	-1,251,055	Closed	-$12.5M	–	101
2021 Q2	$12.5M	Hold	1,251,055	–	–	0.44%	62
2021 Q1	$11.9M	Hold	1,251,055	–	–	0.41%	57
2020 Q4	$13.7M	Hold	1,251,055	–	–	0.44%	50
2020 Q3	$11.1M	Buy	+1,251,055	New	+$14.2M	0.38%	52

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Boxer Capital's PSTX Position: Q4 2024 in Review

Boxer Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2024, closing a stake of 2,000,000 shares — an estimated $5.72M sold.

Boxer Capital first reported a position in PSTX in Q3 2020 and held it in 7 quarters. The position peaked at $14.3M in Q1 2024. 115 funds tracked by Wall St. Rank hold PSTX as of Q4 2024.

Boxer Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Boxer Capital sold 2,000,000 Poseida Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $5.72M.
Boxer Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Boxer Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $14.3M in Q1 2024.
115 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.